摘要
Early diagnosis of cancer can significantly improve treatment and survival outcomes.Imaging and tissue biopsy are the gold standard diagnostic approaches but are costly,invasive,and often unable to detect early-stage tumors.The past decade has marked an acceleration in the discovery and development of liquid biopsy tests for aiding in the detection of various types of tumor markers in non-tissue samples,such as blood.Liquid biopsy markers include circulating tumor cells,as well as tumor cell fragments,nucleic acids,and proteins.Liquid biopsy may be useful in screening patients considered to be at high risk of developing cancer,for refining diagnosis when combined with other test results,and for early detection of recurrence.Advances in big data analytics,informatics,and artificial intelligence will make it possible to combine patient history,clinical data,and liquid biopsy marker profiles to achieve more accurate and earlier diagnosis.In this review,we summarize the current use of liquid biopsy in cancer care,including the development of multi-analyte panels to improve diagnostic accuracy and detect several cancer types in a single assay.We highlight recent advances for potential future applications of liquid biopsy to aid in the diagnosis of early-stage lung cancer.We also discuss the opportunities and challenges of integrating liquid biopsy into current algorithms for cancer screening and diagnosis.
基金
This work was supported by Abbott Laboratories.
